Intricacies of Bevacizumab-Induced Toxicities and Their Management

Annals of Pharmacotherapy

Volumn 43, Issue 3, 2009, Pages 490-501

  Gressett, Sarah M ^a   Shah, Sachin R ^b  

^a VA NORTH TEXAS HEALTH CARE SYSTEM   (United States)

^b TEXAS TECH UNIVERSITY   (United States)

Author keywords

Adverse event, angiogenesis inhibitors; Bevacizumab; Toxicity; Vascular endothelial growth factor

Indexed keywords

ACETYLSALICYLIC ACID; ALPHA2A INTERFERON; ANTICOAGULANT AGENT; ANTITHROMBOCYTIC AGENT; BEVACIZUMAB; CARBOPLATIN; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; FLUOROURACIL; FOLINIC ACID; IRINOTECAN; OXALIPLATIN; PACLITAXEL; PLACEBO; SUNITINIB; VASCULOTROPIN;

ABDOMINAL PAIN; ALOPECIA; ANGIOGENESIS; ANOREXIA; BILE DUCT FISTULA; BLADDER FISTULA; BLEEDING; BONE MARROW SUPPRESSION; BRAIN HEMORRHAGE; BRAIN METASTASIS; BREAST CANCER; BRONCHOPLEURAL FISTULA; CANCER RADIOTHERAPY; CLINICAL TRIAL; CONGESTIVE HEART FAILURE; DEHYDRATION; DIARRHEA; DIGESTIVE SYSTEM PERFORATION; DRUG DOSE COMPARISON; DRUG HYPERSENSITIVITY; DRUG MEGADOSE; DYSPEPSIA; EPISTASIS; FATIGUE; GASTROINTESTINAL HEMORRHAGE; HEADACHE; HUMAN; HYPERTENSION; JAW OSTEONECROSIS; KIDNEY CARCINOMA; KIDNEY FAILURE; LOW DRUG DOSE; LUNG HEMORRHAGE; LUNG NON SMALL CELL CANCER; MORBIDITY; NAUSEA; NEPHROTIC SYNDROME; NEUROPATHY; NEUROSURGERY; NOSE SEPTUM PERFORATION; PAIN; PATHOPHYSIOLOGY; POSTERIOR REVERSIBLE ENCEPHALOPATHY SYNDROME; PRIORITY JOURNAL; PROPHYLAXIS; PROTEINURIA; RECTUM CANCER; REVIEW; RISK FACTOR; SIDE EFFECT; SQUAMOUS CELL CARCINOMA; STOMATITIS; SYNCOPE; THROMBOEMBOLISM; THROMBOTIC THROMBOCYTOPENIC PURPURA; TRACHEOESOPHAGEAL FISTULA; VAGINA BLEEDING; VAGINA DISEASE; VOMITING; WOUND HEALING IMPAIRMENT;

ANGIOGENESIS INHIBITORS; ANTIBODIES, MONOCLONAL; CLINICAL TRIALS AS TOPIC; GASTROINTESTINAL DISEASES; HEART FAILURE; HEMORRHAGE; HUMANS; HYPERTENSION; INTESTINAL PERFORATION; PROTEINURIA; THROMBOEMBOLISM; WOUND HEALING;

EID: 62949129110     PISSN: 10600280     EISSN: None     Source Type: Journal    
DOI: 10.1345/aph.1L426     Document Type: Review

References (60)

1. Kerbel RS. Tumor angiogenesis. N Engl J Med 2008;358:2039-49.
2. Ferrara N, Gerber HP, LeCouter J. The biology of VEGF and its receptors. Nat Med 2003;9:669-76.
3. Bando H. Vascular endothelial growth factor and bevacizumab in breast cancer. Breast Cancer 2007;14:163-73.
4. Jain RK. Normalizing tumor vasculature with anti-angiogenic therapy: a new paradigm for combination therapy. Nat Med 2001 ;7:987-9.
5. Willett CG, Boucher Y, di Tomaso E, et al. Direct evidence that the VEGF-specific antibody bevacizumab has antivascular effects in human rectal cancer. Nat Med 2004; 10:145-7.
6. Hurwitz H, Fehrenbacher L, Novotny W, et al. Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer. N Engl J Med 2004;350:2335-42.
7. Kabbinavar FF, Schulz J, McCleod M, et al. Addition of bevacizumab to bolus fluorouracil and leucovorin in first-line metastatic colorectal cancer: results of a randomized phase H trial. J Clin Oncol 2005;23:3697-705.
8. Giantonio BJ, Catalano PF, Meropol NJ, et al. Bevacizumab in combination with oxaliplatin, fluorouracil, and leucovorin (FOLFOX4) for previously treated metastatic colorectal cancer: results from the Eastern Cooperative Oncology Group Study E3200. J Clin Oncol 2007;25:1539-44.
9. Kabbinavar F, Hurwitz HI, Fehrenbacher L, et al. Phase II, randomized trial comparing bevacizumab plus fluorouracil (FU)/leucovorin (LV) with FU/LV alone in patients with metastatic colorectal cancer. J Clin Oncol 2003;21:60-5.
10. Hochester HS, Hart LL, Ramanathan RK, et al. Safety and efficacy of oxaliplatin and fluoropyrimidine regimens with or without bevacizumab as first-line treatment of metastatic colorectal cancer: results of the TREE study. J Clin Oncol 2008;26:3523-9.
11. Johnson DH, Fehrenbacher L, Novotny WF, et al. Randomized phase II trial comparing bevacizumab plus carboplatin and paclitaxel with carboplatin and paclitaxel alone in previously untreated locally advanced or metastatic non-small-cell lung cancer. J Clin Oncol 2004;22:2184-91.
12. Sandler AB, Gray R, Perry MC, et al. Paclitaxel-carboplatin alone or with bevacizumab for non-small-cell lung cancer. N Engl J Med 2006; 355:2542-50.
13. Miller KD, Wang M, Gralow J, et al. E2100: a randomized phase III trial of paclitaxel versus paclitaxel plus bevacizumab as first-line therapy for locally recurrent or metastatic breast cancer: a trial coordinated by the Eastern Cooperative Oncology Group (abstract 3). Breast Cancer Res Treat 2005:94(suppl 1):S6.
14. Escudier B, Pluzanska A, Koralewski P, et al. Bevacizumab plus interferon alfa-2a for treatment of metastatic renal cell carcinoma: a randomised, double-blind phase III trial. Lancet 2007;370:2103-11.
15. Miller K, Wang M, Gralow J, et al. Paclitaxel plus bevacizumab versus paclitaxel alone for metastatic breast cancer. N Engl J Med 2007;357: 2666-76.
16. Package insert. Avastin (bevacizumab). 2006. San Francisco, CA: Genentech, Inc., August 2008.
17. Package insert. Avastin (bevacizumab). 2005. South San Francisco, CA: Roche, August 2008.
18. Gordon MS, Cunningham D. Managing patients treated with bevacizumab combination therapy. Oncology 2005;69:25-33.
19. Gordon MS, Margolin K, Talpaz M, et al. Phase I safety and pharmacokinetic study of recombinant human anti-vascular endothelial growth factor in patients with advanced cancer. J Clin Oncol 2001;19:843-50.
20. Labidi S, Bachelot T, Coquard IL, et al. Bevacizumab and paclitaxel for breast cancer patients with CNS metastases (abstract). J Clin Oncol 2008;26:12009.
21. Akerley WL, Langer CJ, Oh Y, et al. Acceptable safety of bevacizumab therapy in patients with brain metastases due to non-small-cell lung cancer (abstract). J Clin Oncol 2008;26:8043.
22. Flynn PJ, Sugrue MM, Feng S, et al. Incidence of serious bleeding events in patients with metastatic colorectal cancer receiving bevacizumab as part of a first-line regimen: results from the BRTTE observation cohort study (abstract). J Clin Oncol 2008;26:4104.
23. Hambleton J, Skillings J, Kabbinavar F, et al. Safety of low-dose aspirin (ASA) in a pooled analysis of 3 randomized, controlled trials of bevacizumab with chemotherapy in patients with metastatic colorectal cancer (abstract). J Clin Oncol 2005;23:3554.
24. Kilickap S, Abali H, Celik I. Bevacizumab, bleeding, thrombosis, and warfarin (abstract). J Clin Oncol 2003;21:3542.
25. Roodhart JM, Langenberg MH, Wittevenn E, et al. The molecular basis of class side effects due to treatment with inhibitors of the VEGF/VEGFR pathway. Curr Clin Pharmacol 2008;3:132-43.
26. Scappaticci FA, Fehrenbacher L, Cartwright T, et al. Surgical wound healing complications in metastatic colorectal cancer patients treated with bevacizumab. J Surg Oncol 2005;91:173-80.
27. Sugrue MM, Purdie DM, Feng S, et al. Serious wound healing complications following surgery in patients with metastatic colorectal cancer receiving bevacizumab: results of the BR1TE observational cohort study (abstract). J Clin Oncol 2008;25:4105.
28. Kozloff M, Conn A, Christiansen N, et al. Safety of bevacizumab among patients receiving first-line chemotherapy for metastatic colorectal cancer (MCRC) - preliminary results from a large registry in the US (abstract). J Clin Oncol 2005;23:3566.
29. Sugrue M, Kozloff M, Hainsworth J, et al. Risk factors for gastrointestinal perforations in patients with metastatic colorectal cancer receiving bevacizumab plus chemotherapy (abstract). J Clin Oncol 2006;24:3535.
30. Ferreiro J, Diaz de Corcuera I, Mane JM, et al. Toxicity of bevacizumab in metastatic colorectal carcinoma: analysis in 173 consecutive patients (abstract). J Clin Oncol 2008;26:15069.
31. Scappaticci FA, Skillings JR, Holden SN, et al. Arterial thromboembolic events in patients with metastatic carcinoma treated with chemotherapy and bevacizumab. J Natl Cancer Inst 2007;99:1232-9.
32. Kozloff M, Sugrue M, Berlin J, et al. Safety and effectiveness of bevacizumab and chemotherapy in elderly patients with metastatic colorectal cancer: results from the BRITE prospective cohort study (abstract). J Clin Oncol 2008;26:454.
33. Purdie DM, Berlin JD, Flynn PJ, et al. The safety of long-term bevacizumab use: results from the BRITE observational cohort study (abstract). J Clin Oncol 2008;26:4103.
34. Hesser BA, Liang XH, Camenisch G, et al. Down syndrome critical region protein 1 (DSCR1), a novel VEGF target gene that regulates expression of inflammatory markers on activated endothelial cells. Blood 2004;104:149-58.
35. Kuenen BC, Levi M, Meijers JC, et al. Analysis of coagulation cascade and endothelial cell activation during inhibition of vascular endothelial growth factor/vascular endothelial growth factor receptor pathway in cancer patients. Arterioscler Thromb Vase Biol 2002;22:1500-5.
36. Saif MW, Mehra R. Incidence and management of bevacizumab-related toxicities in colorectal cancer. Expert Opin Drug Saf 2006;5:553-66.
37. The National Cancer Institute Common Toxicity Criteria (CTC) Version 2.0. Revised March 23,1998. http://ctep.cancer.gov/forms/CTCv20-4-30-992.pdf (accessed 2008 May 24).
38. Zhu X, Wu S, Dahut WL, Parikh CR. Risks of proteinuria and hypertension with bevacizumab, an antibody against vascular endothelial growth factor: systematic review and meta-analysis. Am J Kidney Dis 2007;49: 186-93.
39. Raman AK, Lombardo JC, Chandrasekhar R, et al. Bevacizumab related adverse events among various age groups of elderly patients with advanced colorectal cancer (abstract). J Clin Oncol 2007;25:14546.
40. Choi YM, Shord S, Cuellar S, Villano J. Examining ethnic differences for bevacizumab-induced hypertension and proteinuria (abstract). J Clin Oncol 2007;25:21168.
41. Yang JC, Haworth L, Sherry RM, et al. A randomized trial of bevacizumab, and anti-vascular endothelial growth factor antibody, for metastatic renal cancer. N Engl J Med 2003;349:427-34.
42. Pande AU, Lombardo JC, Fakih M, et al. Bevacizumab induced hypertension: a manageable toxicity (abstract). J Clin Oncol 2006;24:13539.
43. Van Heeckeren WJ, Ortiz J, Cooney MM, et al. Hypertension, proteinuria, and antagonism of vascular growth factor signaling: clinical toxicity, therapeutic target, or novel biomarker? J Clin Oncol 2007;25:2993-5.
44. Eskens FA, Verweij J. The clinical toxicity profile of vascular endothelial growth factor (VEGF) and vascular endothelial growth factor receptor (VEGFR) targeting angiogenesis inhibitors; a review. Eur J Cancer 2006; 42:3127-39.
45. Maitland ML, Moshier K, Imperial J, et al. Blood pressure as a biomarker for sorafenib, an inhibitor of vascular endothelial growth factor signaling pathway (abstract). J Clin Oncol 2006;24:2035.
46. Dincer M, Altundag K. Angiotensin-converting enzyme inhibitors for bevacizumab-induced hypertension (letter). Ann Pharmacother 2006;40: 2278-9. Epub 14 Nov 2006. DOI 10.1345/aph.lH244
47. Schrijvers BF, Flyvbjerg A, De Vriese AS. The role of vascular endothelial growth factor (VEGF) in renal pathophysiology. Kidney Int 2004; 65:2003-17.
48. Roncone D, Satoskar A, Nadasdy T, et al. Proteinuria in a patient receiving anti-VEGF therapy for metastatic renal cell carcinoma. Natl Clin Pract Nephrol 2007;3:287-93.
49. Eremina V, Jefferson JA, Kowalewska J, et al. VEGF inhibition and renal thrombotic microangiopathy. N Engl J Med 2008;358:1129-36.
50. Kim NH, Oh JH, Seo JA, et al. Vascular endothelial growth factor (VEGF) and soluble VEGF receptor FLT-1 in diabetic nephropathy. Kidney Int 2005;67:167-77.
51. Gaspari F, Perico N, Remuzzi G. Timed urine collections are not needed to measure urine protein excretion in clinical practice. Am J Kidney Dis 2006;47:1-7.
52. Gross JL, de Azevedo MJ, Silveiro SP. Diabetic nephropathy: diagnosis, prevention, and treatment. Diabetes Care 2005;28:164-76.
53. National Kidney Foundation: K/DOQI clinical practice guidelines and clinical practice recommendations for diabetes and chronic kidney disease. Am J Kidney Dis 2007;49(suppl 2):S 1-179.
54. Constantiner M, Sehgal AR, Humbert L, et al. A dipstick protein and specific gravity algorithm accurately predicts pathological proteinuria. Am J Kidney Dis 2005;45:833-41.
55. Sarafidis PA, Khosla N, Bakris GL. Antihypertensive therapy in the presence of proteinuria. Am J Kidney Dis 2007;49:12-26.
56. Reidy DL, Chung KY, Timoney JP, et al. Bevacizumab 5 mg/kg can be infused safely over 10 minutes. J Clin Oncol 2007;25:2691-5.
57. Glusker P, Recht L, Lane B. Reversible posterior leukoencephalopathy syndrome and bevacizumab. N Engl J Med 2006;354:980-1.
58. Ozcan C, Wong SJ, Hari P, et al. Reversible posterior leukoencephalopathy syndrome and bevacizumab. N Engl J Med 2006;354:981-2.
59. Feldman DR, Ginsberg MS, Baum M, et al. Phase I trial of bevacizumab plus sunitinib in patients with metastatic renal cell carcinoma (abstract). J Clin Oncol 2008;20:5100.
60. Estilo CL, Carlson D. Osteonecrosis of the jaw related to bevacizumab. J Clin Oncol 2008;26:4037-8.